These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

195 related items for PubMed ID: 18552139

  • 1. Antibody mass escalation study in patients with castration-resistant prostate cancer using 111In-J591: lesion detectability and dosimetric projections for 90Y radioimmunotherapy.
    Pandit-Taskar N, O'Donoghue JA, Morris MJ, Wills EA, Schwartz LH, Gonen M, Scher HI, Larson SM, Divgi CR.
    J Nucl Med; 2008 Jul; 49(7):1066-74. PubMed ID: 18552139
    [Abstract] [Full Text] [Related]

  • 2. Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen.
    Bander NH, Trabulsi EJ, Kostakoglu L, Yao D, Vallabhajosula S, Smith-Jones P, Joyce MA, Milowsky M, Nanus DM, Goldsmith SJ.
    J Urol; 2003 Nov; 170(5):1717-21. PubMed ID: 14532761
    [Abstract] [Full Text] [Related]

  • 3. Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors.
    Pandit-Taskar N, O'Donoghue JA, Divgi CR, Wills EA, Schwartz L, Gönen M, Smith-Jones P, Bander NH, Scher HI, Larson SM, Morris MJ.
    EJNMMI Res; 2015 Nov; 5():28. PubMed ID: 25984435
    [Abstract] [Full Text] [Related]

  • 4. Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor.
    Smith-Jones PM, Vallabhajosula S, Navarro V, Bastidas D, Goldsmith SJ, Bander NH.
    J Nucl Med; 2003 Apr; 44(4):610-7. PubMed ID: 12679407
    [Abstract] [Full Text] [Related]

  • 5. Dose escalation trial of indium-111-labeled anti-carcinoembryonic antigen chimeric monoclonal antibody (chimeric T84.66) in presurgical colorectal cancer patients.
    Wong JY, Chu DZ, Yamauchi D, Odom-Maryon TL, Williams LE, Liu A, Esteban JM, Wu AM, Primus FJ, Beatty JD, Shively JE, Raubitschek AA.
    J Nucl Med; 1998 Dec; 39(12):2097-104. PubMed ID: 9867150
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu?
    Vallabhajosula S, Kuji I, Hamacher KA, Konishi S, Kostakoglu L, Kothari PA, Milowski MI, Nanus DM, Bander NH, Goldsmith SJ.
    J Nucl Med; 2005 Apr; 46(4):634-41. PubMed ID: 15809486
    [Abstract] [Full Text] [Related]

  • 9. Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer.
    Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ, Bander NH.
    J Clin Oncol; 2004 Jul 01; 22(13):2522-31. PubMed ID: 15173215
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen.
    Vallabhajosula S, Goldsmith SJ, Hamacher KA, Kostakoglu L, Konishi S, Milowski MI, Nanus DM, Bander NH.
    J Nucl Med; 2005 May 01; 46(5):850-8. PubMed ID: 15872360
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of 111In-DOTA-5D3, a Surrogate SPECT Imaging Agent for Radioimmunotherapy of Prostate-Specific Membrane Antigen.
    Banerjee SR, Kumar V, Lisok A, Plyku D, Nováková Z, Brummet M, Wharram B, Barinka C, Hobbs R, Pomper MG.
    J Nucl Med; 2019 Mar 01; 60(3):400-406. PubMed ID: 30237212
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A prospective pilot study of (89)Zr-J591/prostate specific membrane antigen positron emission tomography in men with localized prostate cancer undergoing radical prostatectomy.
    Osborne JR, Green DA, Spratt DE, Lyashchenko S, Fareedy SB, Robinson BD, Beattie BJ, Jain M, Lewis JS, Christos P, Larson SM, Bander NH, Scherr DS.
    J Urol; 2014 May 01; 191(5):1439-45. PubMed ID: 24135437
    [Abstract] [Full Text] [Related]

  • 15. High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody.
    Richman CM, Denardo SJ, O'Donnell RT, Yuan A, Shen S, Goldstein DS, Tuscano JM, Wun T, Chew HK, Lara PN, Kukis DL, Natarajan A, Meares CF, Lamborn KR, DeNardo GL.
    Clin Cancer Res; 2005 Aug 15; 11(16):5920-7. PubMed ID: 16115934
    [Abstract] [Full Text] [Related]

  • 16. First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake.
    Pandit-Taskar N, O'Donoghue JA, Ruan S, Lyashchenko SK, Carrasquillo JA, Heller G, Martinez DF, Cheal SM, Lewis JS, Fleisher M, Keppler JS, Reiter RE, Wu AM, Weber WA, Scher HI, Larson SM, Morris MJ.
    J Nucl Med; 2016 Dec 15; 57(12):1858-1864. PubMed ID: 27516450
    [Abstract] [Full Text] [Related]

  • 17. Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer.
    Tagawa ST, Milowsky MI, Morris M, Vallabhajosula S, Christos P, Akhtar NH, Osborne J, Goldsmith SJ, Larson S, Taskar NP, Scher HI, Bander NH, Nanus DM.
    Clin Cancer Res; 2013 Sep 15; 19(18):5182-91. PubMed ID: 23714732
    [Abstract] [Full Text] [Related]

  • 18. Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors.
    Milowsky MI, Nanus DM, Kostakoglu L, Sheehan CE, Vallabhajosula S, Goldsmith SJ, Ross JS, Bander NH.
    J Clin Oncol; 2007 Feb 10; 25(5):540-7. PubMed ID: 17290063
    [Abstract] [Full Text] [Related]

  • 19. Radiation absorbed dose estimation for 90Y-DOTA-biotin with pretargeted NR-LU-10/streptavidin.
    Breitz HB, Fisher DR, Goris ML, Knox S, Ratliff B, Murtha AD, Weiden PL.
    Cancer Biother Radiopharm; 1999 Oct 10; 14(5):381-95. PubMed ID: 10850323
    [Abstract] [Full Text] [Related]

  • 20. Biodistributions of 177Lu- and 111In-labeled 7E11 antibodies to prostate-specific membrane antigen in xenograft model of prostate cancer and potential use of 111In-7E11 as a pre-therapeutic agent for 177Lu-7E11 radioimmunotherapy.
    Pan MH, Gao DW, Feng J, He J, Seo Y, Tedesco J, Wolodzko JG, Hasegawa BH, Franc BL.
    Mol Imaging Biol; 2009 Oct 10; 11(3):159-66. PubMed ID: 19034582
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.